4.7 Article

Catalytic Nanomedicine as a Therapeutic Approach to Brain Tumors: Main Hypotheses for Mechanisms of Action

期刊

NANOMATERIALS
卷 13, 期 9, 页码 -

出版社

MDPI
DOI: 10.3390/nano13091541

关键词

catalytic nanomedicine; bionanocatalyst; cancer therapy; nanoparticle; mitochondria

向作者/读者索取更多资源

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor that is difficult to completely remove through surgery due to its growth in normal brain tissue. Catalytic Nanomedicine has made important advancements in developing bionanocatalysts that can selectively disrupt the genetic material of cancer cells without harming healthy cells. This review provides a detailed description of these nanoparticles and their potential mechanisms of action, as well as a case report on the treatment of a GBM patient with bionanocatalysts following surgery. Future research needs to bridge the knowledge gaps before the clinical translation of these promising compounds.
Glioblastoma multiforme (GBM) is the most aggressive primary malignant tumor of the brain. Although there are currently a wide variety of therapeutic approaches focused on tumor elimination, such as radiotherapy, chemotherapy, and tumor field therapy, among others, the main approach involves surgery to remove the GBM. However, since tumor growth occurs in normal brain tissue, complete removal is impossible, and patients end up requiring additional treatments after surgery. In this line, Catalytic Nanomedicine has achieved important advances in developing bionanocatalysts, brain-tissue-biocompatible catalytic nanostructures capable of destabilizing the genetic material of malignant cells, causing their apoptosis. Previous work has demonstrated the efficacy of bionanocatalysts and their selectivity for cancer cells without affecting surrounding healthy tissue cells. The present review provides a detailed description of these nanoparticles and their potential mechanisms of action as antineoplastic agents, covering the most recent research and hypotheses from their incorporation into the tumor bed, internalization via endocytosis, specific chemotaxis by mitochondrial and nuclear genetic material, and activation of programmed cell death. In addition, a case report of a patient with GBM treated with the bionanocatalysts following tumor removal surgery is described. Finally, the gaps in knowledge that must be bridged before the clinical translation of these compounds with such a promising future are detailed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据